July 15, 2022
NIPRO CORPORATION

Notice of Series A Investment in Nanotis, a University ofTokyo-affiliated Startup Engaging in the Development ofSaliva-Based Digital Infection Testing Technologies
NIPRO CORPORATION (Head Office: Kita-ku, Osaka; President: Yoshihiko Sano; hereinafter"NIPRO") hereby announces that it made a series A investment in Nanotis Corporation (HeadOffice: Shibuya-ku, Tokyo; CEO and Founder: Lisa Sakashita; hereinafter "Nanotis"), a Universityof Tokyo-affiliated startup engaging in the development of next-generation saliva-based digital
infection testing technologies, on July 5, 2022.
１． Purpose of Investment
Nanotis is a venture company collaborating with the University of Tokyo to develop
saliva-based digital testing technologies covering a wide range of virus inspections including
COVID-19 and flu. In particular, Nanotis successfully developed a technology called "Nucleic
Acid Navigated Optically Traceable Immuno‐Sensing (NANOTIS method)," which, when
implemented, will achieve simple, quick and affordable saliva-based testing with excellent
accuracy. With the NANOTIS method, test results will be digitally processed and aggregatedin a single step, and it has the potential to become a core technology for future telemedicine,
administrative data accumulation, and efficient infection control.
The COVID-19 pandemic created a global awareness of the importance of routine screening
testing regardless of the presence or absence of symptoms. Genetic testing methods such as
PCR are accurate but require time and specialized techniques and equipment whereas
antigen testing such as immunochromatography* is simple and affordable but lacks
sensitivity. For either type of testing, samples must be invasively collected using
nasopharyngeal swabs, in most cases, and data accumulation requires manual input. TheNANOTIS method is a next-generation platform offering a third option for infection testing.
Boasting a wealth of knowledge and know-how in manufacturing and distributing
diagnostic products, NIPRO recently launched "NIPRO Heart Line™," a watch-over support
system with telemedicine support features, and commenced the joint development of "asystem for predicting COVID-19 progression" with the University of Tokyo Hospital. Bymaking this series A investment in Nanotis with a view to future collaboration, NIPRO

accelerates its growth toward becoming a leading company in infection diagnostics with aseries of comprehensive platforms covering everything from innovative testing technologies totelemedicine and data analytics.
* Immunochromatography: An immunoassay technique applied in pregnancy and flu diagnosis, etc. whereby theproperties of samples slowly flow over cellulose membranes while dissolving reagents (capillarity).

２． Method of Stock Acquisition
NIPRO acquired all of the Class A preferred shares issued by Nanotis on July 5, 2022.

３． Company Profile of Nanotis
Name: Nanotis Corporation
CEO and Founder: Lisa Sakashita
Address: 5-50-13 Yoyogi, Shibuya-ku, Tokyo 151-0053
Joint research lab: University of Tokyo Engineering Bldg. 4, 7-3-1 Hongo, Bunkyo-ku, Tokyo113-8656
Founded: June 6, 2016
Capital (inc. capital reserve): 388,150,240 JPY
URL:http://nanotis.net [nanotis.]

４． Impact on Business Performance
The impact on business performance for the current fiscal year is expected to be negligible.